Factors in second-generation antipsychotic switching patterns in a national sample of older veterans with schizophrenia

Psychiatric Services

Volumn 62, Issue 1, 2011, Pages 47-53

  Dassori, Albana M ^a,b   Copeland, Laurel A ^c,d   Zeber, John E ^c,d   Miller, Alexander L ^b  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; DIABETES MELLITUS; DRUG SUBSTITUTION; DYSLIPIDEMIA; ETHNICITY; FEMALE; GENDER; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; OBESITY; RACE; SCHIZOPHRENIA; VETERAN;

EID: 79953035151     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.62.1.pss6201_0047     Document Type: Article

References (25)

1. Marder SR, Essock SM, Miller AL, et al: Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 161:1334-1349, 2004 (Pubitemid 38989085)
2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al: Consensus development conference on antipsychotic drugs and obesity and diabetes. Journal of Clinical Psychiatry 65:267-272, 2004
3. Nasrallah HA, Newcomer JW: Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. Journal of Clinical Psychopharmacology 24:S7-S14, 2004 (Pubitemid 39265949)
4. Spoelstra JA, Stolk RP, Cohen D, et al: Antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus. Journal of Clinical Psychiatry 65:674-678, 2004
5. McEvoy JP, Meyer JM, Goff DC, et al: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 80:19-32, 2005 (Pubitemid 41587460)
6. American Diabetes Association: Standards of medical care in diabetes, 2008. Diabetes Care 31(suppl 1):S12-S54, 2008
7. Total Prevalence of Diabetes and Pre-Diabetes. Alexandria, Va, American Diabetes Association, 2010. Available at www.diabe tes.org/diabetes-basics/ diabetes-statistics
8. Buckley PF, Correll CU: Strategies for dosing and switching antipsychotics for optimal clinical management. Journal of Clinical Psychiatry 69(suppl 1):4-17, 2008
9. Morrato EH, Newcomer JW, Kamat S, et al: Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 32:1037-1042, 2009
10. Owen RR, Feng W, Thrush CR, et al: Variations in prescribing practices for novel antipsychotic medications among Veterans Affairs hospitals. Psychiatric Services 52:1523-1525, 2001 (Pubitemid 33029594)
11. Lamberti JS, Costea GO, Olson D, et al: Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates. Journal of Clinical Psychiatry 66:900-906, 2005 (Pubitemid 41032832)
12. Mackin P, Watkinson HM, Young AH: Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia 48:215-221, 2005 (Pubitemid 40543292)
13. de Leon J, Diaz FJ, Josiassen RC, et al: Weight gain during a double-blind multi-dosage clozapine study. Journal of Clinical Psychopharmacology 27:22-27, 2007 (Pubitemid 46105759)
14. Krakowski M, Czobor P, Citrome L: Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophrenia Research 110:95-102, 2009
15. Brown S: Excess mortality of schizophrenia: a meta-analysis. British Journal of Psychiatry 171:502-508, 1997
16. Parks J, Svendsen D, Singer P, et al: Morbidity and Mortality in People With Serious Mental Illness. Technical report 13. Alexandria Va, National Association of State Mental Health Program Directors Medical Directors Council, 2006
17. Kazis LE, Miller DR, Clark J, et al: Health-related quality of life in patients served by the Department of Veterans Affairs: results from the Veterans Health Study. Archives of Internal Medicine 158:626-632, 1998 (Pubitemid 28144820)
18. Shen Y, Hendricks A, Zhang S, et al: VHA enrollees' health care coverage and use of care. Medical Care Research and Review 60:253-267, 2003 (Pubitemid 36605436)
19. Pugh MJ, Copeland LA, Zeber JE, et al: The impact of epilepsy on health status among younger and older adults. Epilepsia 46:1820-1827, 2005
20. International Classification of Diseases, 9th Revision, Clinical Modification, 6th ed. Geneva, World Health Organization, 2008
21. Selim AJ, Fincke G, Ren XS, et al: Comorbidity assessments based on patient report: results from the Veterans Health Study. Journal of Ambulatory Care Management 27:281-295, 2004 (Pubitemid 38780398)
22. Wickens TD: Multiway Contingency Tables Analysis for the Social Sciences. Hillsdale, NJ, Erlbaum, 1989
23. Krein SL, Hofer TP, Kerr EA, et al: Whom should we profile? Examining diabetes care practice variation among primary care providers, provider groups, and health care facilities. Health Services Research 37:1159-1180, 2002 (Pubitemid 35398454)
24. Lambert MT, Copeland LA, Sampson N, et al: New-onset type-2 diabetes associated with atypical antipsychotic medications. Progress in Neuro-psychopharmacology and Biological Psychiatry 30:919-923, 2006 (Pubitemid 43795373)
25. Evans S, Newton R, Higgins S: Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Australian and New Zealand Journal of Psychiatry 39:479-486, 2005 (Pubitemid 40932626)